Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies
Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies
复制标题
DOI：
10.1007/s40273-021-01079-6
复制
发表时间：
2021-09-23
影响因子：
4.4
通讯作者：
Lin, Pei-Jung
中科院分区：
文献类型：
--
作者：
Mattingly, T. Joseph, II;McQueen, R. Brett;Lin, Pei-Jung
在美国，治疗阿尔茨海默病(AD)的新疗法包括100多种不同的药物，其中80%可以归类为疾病修饰疗法。疾病改良剂aducanumab的监管批准使人们更加关注AD诊断、评估和治疗的复杂性，以及随着这一领域的创新继续下去，支付者和政策制定者在未来几年将面临的困难决定。AD治疗的价值可以根据分析的角度、数据来源和价值评估的方法而有很大的不同。本文侧重于AD特定的数据差距和测量挑战，并为证据生成提供指导，以促进对未来AD治疗的更好价值评估。
The pipeline for new treatments for Alzheimer's disease (AD) in the USA contains over 100 different agents, 80% of which can be categorized as disease-modifying therapies. The regulatory approval of the disease-modifying agent aducanumab has brought more attention to the complexity of the diagnosis, evaluation, and treatment of AD and the difficult decisions payers and policy makers will face over the next few years as innovation continues in this space. The value of AD treatment can vary widely according to the perspective of the analysis, sources of data, and methodological approach for the value assessment. This article focuses on AD-specific data gaps and measurement challenges and provides guidance for evidence generation to facilitate better value assessments for future AD treatments.